ArticleAmerican journal of translational research2025
Effects of oral OsteoKing on pain, lumbar function, and inflammatory markers in patients with lumbar disc herniation.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effects of oral administration of OsteoKing on pain, lumbar spine function, and serological indicators in patients with lumbar disc herniation (LDH).
methodA retrospective analysis was conducted on clinical information of 266 LDH patients treated at Jilin Academy of Chinese Medicine Sciences between October 2023 and March 2024. According to treatment method, patients were divided into the conventional group (Celecoxib treatment) and the OsteoKing group (OsteoKing). Clinical outcomes were compared between the two groups, and ordinal logistic regression analysis was conducted to identify factors influencing the therapeutic efficacy of OsteoKing.
resultAfter treatment, the OsteoKing group demonstrated significantly better treatment outcomes and greater improvement in lumbar spine function compared to the conventional group (
conclusionOsteoKing effectively alleviates pain, improves lumbar spine function, and reduces serum inflammatory factor levels in patients with LDH, thereby mitigating inflammatory responses. Additionally, OsteoKing significantly enhances patients' quality of life, with high safety and good patient satisfaction, supporting its clinical value as a therapeutic option.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.